52 results about "Drug uptake" patented technology

The invention belongs to the technical field of pharmaceutical preparations, and relates to traditional Chinese medicine self-assembled nanoparticles for enhancing anti-inflammatory activity as well as a preparation method and application of the traditional Chinese medicine self-assembled nanoparticles. The traditional Chinese medicine self-assembled nanoparticles are prepared from biphenyl cyclooctene type lignan and an oleanane type pentacyclic triterpenoid compound, wherein the mass ratio of the biphenyl cyclooctene type lignan to the oleanane type pentacyclic triterpenoid compound is 1 to (0.125 to 8). Through an anti-solvent exchange method, the carrier-free nanoparticles based on self-assembly of the traditional Chinese medicine active ingredients are prepared by utilizing spontaneous non-covalent interaction between the biphenyl cyclooctene lignan and the oleanane pentacyclic triterpenoid, so that the cytotoxicity is remarkably reduced, the biocompatibility is enhanced, and the toxic and side effects are reduced; meanwhile, the traditional Chinese medicine self-assembled nano-particles have a remarkable cellular uptake effect, the absorption and utilization efficiency of the medicine is improved, and more efficient anti-inflammatory biological activity is shown.

The invention discloses a perfusion-free parallel double-cell intestine-liver chip system and application thereof in drug uptake evaluation, and belongs to the field of biomedical engineering and organ chips. The chip disclosed by the invention is simple in structure, free of an external pump and a complex pipeline, capable of realizing fluid circulation through swinging, convenient to operate, low in cost and small in pollution risk, and also capable of promoting cell differentiation and optimizing hepatocyte functions. The chip integrates a parallel intestinal cell and a liver cell which are communicated through a shared channel, can continuously simulate intestinal absorption and liver first-pass metabolism, and is closer to an in-vivo physiological state. The device adopts a detachable transparent modular design, can be repeatedly used, supports multi-group parallel operation, can improve experimental flux and result repeatability, and is suitable for in-vitro verification of drug absorption, permeability and metabolism evaluation.

A microneedle array system with heterogeneous needles, designed for the enhanced transdermal delivery of bioactive agents for therapeutic and diagnostic purposes. This system includes a variety of microneedle 140 configurations, such as primary and secondary microneedles that differ in size, shape, and material to optimize delivery and functionality. Secondary needles are specifically designed with additional features such as sensors, specialized coatings, and microelectronics to perform tasks beyond simple delivery, such as in-situ detection and measurement of physiological responses, and stimulation for enhanced drug absorption and therapeutic effect.

The utility model relates to a capsule dosing device for rhesus monkeys, which comprises a thick tube and a thin tube, the thin tube is movably mounted in the thick tube in a penetrating manner, and a claw-shaped clamp is arranged at the bottom of the thick tube; the claw-shaped clamp comprises mounting blocks, the mounting blocks are fixedly mounted on the left inner wall and the right inner wall of the thick pipe correspondingly, first springs are fixedly mounted at the bottoms of the two mounting blocks correspondingly, a movable block is fixedly mounted between the bottoms of the two first springs, and a connecting rod is movably mounted at the bottom of the movable block; and adjusting plates are movably mounted at the bottoms of the connecting rods. The capsule administration device for the rhesus monkey can prevent the rhesus monkey from crushing the capsule to influence the accuracy of the administration amount and the drug absorption, so that the success rate of capsule administration can reach 100%, the test quality is ensured, and effective reference is provided for clinical medication; and moreover, the possibility that the teeth of the rhesus monkey hurt people during capsule administration can be effectively avoided, and the safety of people is guaranteed to the greatest extent.

The present application relates to the technical field of artificial intelligence, and particularly relates to an individualized medication prediction method based on artificial intelligence, comprising: acquiring a plurality of standard historical medical data sets; acquiring metabolic capacity scores and drug metabolism rates corresponding to all data groups; training to obtain relationship models corresponding to all standard historical medical data sets; acquiring liver metabolism parameters, gene expression parameters and each drug name in a treatment scheme of a patient to obtain a drug metabolism rate; and determining a corresponding prediction drug amount determination method according to whether the drug types in the treatment scheme have a competitive relationship. The present application integrates drug metabolism enzyme-related gene expression and liver metabolism function, simultaneously incorporates drug absorption competition and metabolism enzyme competition when drugs are used in combination, corrects the final output prediction drug amount when drugs are used in combination, so that the model is more suitable for the actual drug use scene, and the accuracy of the prediction result is increased.

This application discloses a sustained-release formula and medicated pillow for the prevention and treatment of allergic rhinitis, including a pillow base with two symmetrically arranged sustained-release mechanisms and a drive mechanism in the bottom mounting compartment. The sustained-release mechanism consists of multiple sustained-release components, each containing a sustained-release tube and a drug storage tube, connected by a U-shaped connecting pipe and a one-way valve; the drug storage tube is inserted into a pierced tube with a filter screen, which balances air pressure and prevents contamination. The drive mechanism drives a sliding valve to reciprocate via a worm gear system, achieving quantitative drug extraction and precise sustained-release; the atomization design of the sustained-release port improves drug absorption efficiency, and the guide holes in the mounting compartment and the ventilation grooves on the pillow surface form a uniform diffusion channel. This solution solves the problems of cumbersome drug replacement, uncontrollable volatilization, and easy deterioration associated with traditional medicated pillows, offering advantages such as precise controlled release, convenient maintenance, and multiple safety protections. It allows for individualized drug administration based on drug characteristics and patient rhythms, significantly improving the effectiveness of sleep aid therapy and the user experience.

The utility model discloses a kind of venous hot compress sleeve, including the rectangular block of the sleeve main body made of skin-friendly material, sleeve main body is equipped with heating area, the left side of sleeve main body is equipped with first connecting belt, the right side of sleeve main body is equipped with second connecting belt, corresponding position of first connecting belt and second connecting belt is equipped with detachable connecting piece respectively, the position of first connecting belt close to sleeve main body is equipped with infusion leather strip connecting piece, the position of second connecting belt close to sleeve main body is equipped with elastic tightness area.The utility model can realize temperature controllable and heat preservation to a certain extent, improve hot compress operation convenience and security, not only can help patient expand venous vessel, promote drug absorption, also can relieve pain caused by vasospasm, reduce swelling or induration.

The invention discloses a gene therapy nose drop for preventing and / or treating coronavirus as well as preparation and application of the gene therapy nose drop, and belongs to the technical field of biological medicines. The nose drop comprises a reagent A and a reagent B. The reagent A is a nano-gene therapy drug solution connecting a self-assembled composite nano-material carrier and a targeted nucleic acid cleavage system through a click reaction, and the cleavage system comprises endonuclease molecules and an hpDNA oligonucleotide probe set. The hpDNA probe can target a coronavirus N gene conserved sequence and a host cell CtslmRNA at the same time through stem-loop structural design, can cut virus RNA to inhibit replication of the virus RNA, and can block the activation process of virus spike protein; the reagent B is an inhalable preparation of an anti-inflammatory chemical drug, and the drug absorption efficiency is remarkably improved by regulating inflammatory reaction. The nose drop can efficiently prevent and treat coronavirus infection and respiratory tract complications caused by the coronavirus infection through a triple mechanism of'gene editing-host regulation-anti-inflammatory treatment 'in combination with the advantage of nasal local administration, and has the obvious characteristics of high bioavailability and low system toxicity.

Compositions for the treatment of acute manifestations because of oxidative injury by reactive oxygen species (ROS) and chronic development of fibrosis are provided. Compositions of the present invention include perfluorocarbon, hydrogen and oxygen gas, N-acetylcysteine, and glycine to counter robust oxidative responses unleashed following injury from both mechanical and non-mechanical conditions. Methods are also disclosed for delivery to challenging locations (olfactory cleft, spinal canal) and in hostile conditions (post trauma brain, spine, and upper and lower airways), with the invention's products "calming" inflamed tissue by neutralizing ROS in both acute and later complications. Active pharmaceutical ingredient(s) can also be employed to provide both acute and chronic benefit, and such active ingredients themselves can be augmented by the composition, enabling increased drug uptake and oxygenation. The present invention provides broad relief in many conditions for both human and companion subjects.

This invention provides a device for applying ointments for rheumatic and immunological diseases, comprising a box body with an ointment chamber at the top and a buffer chamber inside the box body, the buffer chamber having a flat opening; a control rod rotatably connected to the inner cavity of the buffer chamber, a buffer plate being provided on one side of the control rod, and a first spring connecting the buffer plate and the buffer chamber; a conveyor plate rotatably mounted inside a cylindrical chamber, the conveyor plate having multiple transfer grooves evenly distributed around its circumference; a first tube being provided on the top side of the cylindrical chamber and a second tube being provided on the bottom side; a drive mechanism capable of driving the conveyor plate to rotate. The ointment continuously flowing into the buffer chamber pushes the buffer plate towards the bottom of the buffer chamber, and the first spring also provides an elastic force that pushes the buffer plate upwards. Under the mutual pushing action of the ointment and the buffer plate, the ointment is compressed, reducing gaps and air bubbles, and is discharged from the flat opening, resulting in a uniform and dense ointment without gaps, eliminating the need for secondary coating and repair, and reducing drug waste while ensuring drug absorption.

The invention relates to an efficient, stable and high-biocompatibility nano delivery carrier and application thereof in targeted delivery of drugs, and belongs to the technical field of biological medicines and nano materials. The invention relates to an efficient, stable and high-biocompatibility nano delivery carrier. Mainly comprises a microcrystalline carbon cluster set (the microcrystalline carbon cluster set is composed of a large number of microcrystalline carbon nanosheets), phospholipid bimolecular layers on the surfaces of the microcrystalline carbon nanosheets, oxygen functional groups on the microcrystalline carbon nanosheets and a plurality of surface functional modifications on the oxygen functional groups, and the microcrystalline carbon cluster set comprises, by mass, 91-97 parts of carbon and 3-9 parts of oxygen, the microcrystalline carbon cluster set has a porous structure, the aperture is 2-50nm, and the particle size is 50-200nm. The high-efficiency, stable and high-biocompatibility nano delivery carrier prepared by the invention is granular, controllable in size and highly stable in structure, and can be stored for a long time under conventional conditions without deterioration. According to the present invention, various types of drugs can be loaded, the affinity and the targeting property on various cells can be regulated, the drug absorption efficiency can be substantially improved, the treatment effect can be enhanced, the stability is high after the drug enters the organism, the biocompatibility and the safety are high, and the large-batch production can be achieved;

The invention provides an isoalantolactone derivative TYJ2517, namely 3, 4, 5-trimethoxybenzyl aminomethyl 3-demethyleneisoalantolactone as well as preparation and application thereof, and relates to the field of medicinal compounds, the structure of the isoalantolactone derivative is shown as follows: although many anti-cancer drugs have anti-cancer ability, the drugs generate toxicity to normal cells, and the drugs cannot generate toxicity to the normal cells. Therefore, the development of selective anti-cancer active drugs safe to normal cells is particularly important. According to the invention, TYJ2517 is synthesized, the IC50 value of the TYJ2517 to MCF-7 cells is 3.6 + / -0.8 [mu] M, and the IC50 value of the TYJ2517 to L-02 normal cells exceeds 100 [mu] M. A cell drug uptake capability test result shows that the TYJ2517 uptake capability of L-02 normal cells is low, and the TYJ2517 uptake capability of MCF-7 cancer cells is high. When the administration time is 1 hour, the selective anti-cancer index (SI) of the TYJ2517 to MCF-7 breast cancer cells and L-02 normal cells exceeds 40. Mechanism research shows that the activity of the TYJ2517 for resisting MCF-7 cancer cells is a result of inhibiting the expression quantity of PARP1 protein kinase and ROS, inducing early and late apoptosis of the MCF-7 cells and hindering migration and colony of the MCF-7 cells.

This invention discloses a device and method for evaluating in vitro drug absorption under hypergravity conditions, belonging to the field of medical device technology. The device structure includes: a centrifuge, a centrifuge container, and drug absorption evaluation unit units. Each centrifuge container contains multiple sequentially arranged drug absorption evaluation unit units. Each drug absorption evaluation unit includes a supply chamber, a receiving chamber, an intestinal explant, and a microporous mesh. The supply chamber and receiving chamber are positioned opposite each other, with the intestinal explant sandwiched between them. The supply chamber has at least one supply channel, and the receiving chamber has a receiving cavity paired with the supply channel. Each receiving cavity is topped with a microporous mesh to inhibit deformation of the intestinal explant under hypergravity conditions. This device combines structural simplification, preservation of physiological relevance, and ease of detection. Combined with a spectral correction model, it enables accurate and reliable in vitro hypergravity drug absorption studies.

The application discloses application of GCLC in enhancing cell uptake of BNCT drugs. Boron neutron capture therapy (BNCT) has become a promising method for treating osteosarcoma, and the treatment effect depends to a great extent on 10 Accumulation and distribution of B compounds in tumors. The application provides a gene marker capable of enhancing tumor cell uptake of BNCT drugs and application thereof, and proves that targeting GCLC can overcome the limitation of tumor heterogeneity on BNCT drug uptake by utilizing tumor-specific vulnerability.

The invention discloses an application device for burn wound repair, and belongs to the technical field of burn application equipment.The application device comprises a body surface application layer, a reagent limiting and releasing layer and a medicine storage layer, the body surface application layer is tightly attached to burn skin, net-shaped small holes are formed in the body surface application layer, the reagent limiting and releasing layer is arranged above the body surface application layer, and the medicine storage layer is arranged above the reagent limiting and releasing layer. The body surface pasting layer is fixedly connected with the reagent limiting and releasing layer, and the medicine storage layer is connected with the reagent limiting and releasing layer. In order to overcome the defects that an existing burn application is inconvenient to change medicine, uneven in medicine absorption, poor in application adaptability and the like, the invention provides the application device for repairing burn wounds, and the problems that secondary trauma is easily caused when a traditional application is replaced, residual medicine affects new medicine effect exertion, and the traditional application is difficult to attach to wounds in different shapes are effectively solved.

The application discloses a Sting agonist liposome-warm sensitive gel, a preparation method and application thereof. The Sting agonist liposome-warm sensitive gel comprises a Sting agonist-loaded liposome and a warm sensitive gel, and the preparation method comprises the following steps: preparing the Sting agonist-loaded liposome, adding the warm sensitive gel into a prepared Sting agonist-loaded liposome solution, and stirring until completely dissolved, and the Sting agonist liposome-warm sensitive gel is obtained. The Sting agonist liposome-warm sensitive gel has the advantages of small liposome particle size, good stability, effectively improved cell entry and release behavior of the Sting agonist, avoided burst release effect, in-vivo continuous and stable stimulation of the Sting agonist, better drug efficacy, increased local drug concentration and reduced side effects; the gel matrix can protect the integrity of the liposome and improve the stability of the liposome. The advantages of the liposome and the gel are combined, the drug uptake into cells is increased, and good sustained and controlled release performance is achieved.

The invention belongs to the technical field of pharmaceutical preparations, and provides a probucol sustained-release capsule for reducing the blood fat level and a preparation method thereof, and the probucol sustained-release capsule is prepared by filling a capsule shell with sustained-release pellets, the sustained-release pellet comprises a blank pellet core, a medicine carrying layer, an isolating layer and a sustained-release layer from inside to outside, wherein the medicine carrying layer comprises probucol and an adhesive in a mass ratio of (200-250): (8-12); the slow-release layer is prepared from eudragit RL PO, a plasticizer, a pore-foaming agent and an anti-sticking agent according to the mass ratio of (250 to 300) to (20 to 25) to (20 to 22) to (10 to 18); the pore-foaming agent is prepared from polyethylene glycol 400 and PVP K25 in a mass ratio of (8-12): (3-5). The probucol sustained-release capsule provided by the invention not only has an excellent sustained-release effect, but also enables drug absorption to be less affected by gastric emptying, reduces stimulation to gastrointestinal tracts, and can improve patient compliance.

This invention discloses a safe and controllable injection system for subcutaneous infusion of preparations, comprising: a shell with an internal cavity for accommodating a reservoir; a reservoir, installed within the cavity, for storing the infused drug solution; a drive assembly, located within the shell and connected to the reservoir for applying a continuous thrust to the reservoir; and a micro-infusion tubing, one end of which is sealed to the outlet of the reservoir, and the other end of which is equipped with an injection needle for puncturing subcutaneous tissue, the needle having an internal micro-volume flow path to reduce residual drug solution within the tubing. This invention uses a constant-force spiral spring as the drive source, combined with a flow-limiting tube with precisely controlled inner diameter, to provide a stable and controllable driving force throughout the infusion process, ensuring uniform drug infusion within a predetermined time, improving the stability and efficacy of drug absorption; furthermore, the infusion process eliminates the need for continuous hand-held operation by medical personnel, saving medical resources.

The invention belongs to the technical field of traditional Chinese medicine preparations, and discloses a preparation method of a Mongolian medicine patch. The patch is a multi-layer skeleton type transdermal drug delivery system and sequentially comprises a backing layer, a drug matrix layer and a protective layer from outside to inside, and the drug matrix layer is double-layer composite hydrogel composed of a drug storage layer and a controlled release layer; mango seeds, syzygium jambos and caesalpinia cristae serve as main medicine components, freeze-dried powder is obtained after water extraction, alcohol precipitation and freeze drying are conducted, the freeze-dried powder is mixed with a matrix containing a transdermal enhancer, and then the skin care product is prepared through the steps of sequential coating, pre-curing and the like. According to the patch, the chemical penetration enhancer is added into the matrix, so that the skin cuticle can be softened, the patch medicine is promoted to permeate into the skin, and the problem of low medicine absorption efficiency is effectively avoided.

The application discloses a high-pressure injector for scar hard area injection and belongs to the technical field of medical devices.The application solves the problems that the prior art is difficult to meet the drug delivery requirements of the scar hard area due to unstable propulsion, lacks objective quantitative basis, and is easy to cause uneven drug distribution and poor treatment effect, generates targeted injection parameters suitable for different scar levels by accurately deconstructing the multi-level hardness and thickness of the scar, improves the adaptability of injection data and individual scar characteristics by combining dynamic comparison and benchmark optimization during the injection process, simultaneously predicts the postoperative scar softening progress and drug absorption effect in advance, synchronously builds a multi-grade early warning mechanism, and accurately transmits injection pressure related risks through the differential light signals of warning lights, so that the accuracy and individualization level of scar injection treatment are effectively improved, and the safety and controllability of the injection process are enhanced.

Polysiloxane based microfluidic devices exhibiting significantly less drug absorption with addition of hydrophilic copolymer additive and / or pretreatment with therapeutic agent.

Microphysiological platforms are configured for measuring kinetic rates relating to drug absorption. These kinetic rates include GI region-specific kinetic rates of drug absorption. The kinetic rates include bioavailability of the drug over time in various tissues. The kinetic rates include drug permeability in various tissues. The kinetic rates include measurements of microbial transformations that occur. The kinetic rates include measured effects of gastric emptying and transit times. The kinetic rates include measurements of fasting and fed states for various tissues.

The present application relates to the technical field of physiological monitoring, and particularly relates to a hepatocellular carcinoma treatment effect analysis system and method based on metabolic comprehensive analysis, which comprises the following steps: obtaining the evolution of hepatocellular carcinoma, the composition of drugs and the composition of metabolites; performing drug absorption and conversion analysis based on the composition of drugs and the composition of metabolites and the marker condition; predicting future drug conversion components based on the drug absorption and conversion analysis results and the evolution of hepatocellular carcinoma; and performing drug treatment effect early warning based on the future drug conversion component prediction, correcting the first-pass effect through mass spectrometry imaging and enzyme activity, quantifying the inhibition effect of the tumor microenvironment on drug conversion, and dynamically adjusting the prediction by using the future tumor abnormal score ratio, thereby improving the accuracy of the timing of drug replacement.

The present invention provides a pharmaceutical composition comprising a drug with low solubility and / or low permeability and an ionic liquid, wherein the ionic liquid is an anion ingredient and a cation ingredient, the anion ingredient is oleic acid or isostearic acid, and the cation ingredient is selected from a cationic lipid as well as a transmucosal absorption enhancer or a gastrointestinal absorption enhancer comprising an ionic liquid, wherein the ionic liquid is an anion ingredient and a cation ingredient, the anion ingredient is oleic acid or isostearic acid, and the cation ingredient is selected from a cationic lipid.

Disclosed herein is a method of promoting drug uptake via TRPC1 channels using a pulsed electromagnetic field (PEMF). Also disclosed herein are methods of treating cancer using PEMF adjuvant therapy and methods of selecting cancer patients for PEMF adjuvant therapy by detecting TRPC1 levels in a cancer sample.

The invention discloses application of sodium aescinate or an isomer thereof as a novel penetration enhancer, and belongs to the technical field of pharmaceutical preparations. Sodium aescinate or an isomer thereof is used as a penetration enhancer, and by opening a close connection structure between cells, the penetration of a drug through a cell bypass is promoted, and the absorption efficiency of the drug is improved, so that the bioavailability of a mucous membrane administration preparation is further improved, especially the compatibility of low-permeability drugs. Compared with a traditional penetration enhancer, the sodium aescinate penetration enhancer is non-toxic and non-irritant, can quickly recover to the tight connectivity between mucous membrane tissue cells before administration, does not cause damage to mucous membrane tissues of an absorption part, shows excellent safety, and has a very wide application prospect.

The invention relates to the technical field of biological medicines, and particularly provides a piracetam pharmaceutical composition and a compound preparation. The racetam pharmaceutical composition is prepared from a piracetam drug and dextroborneol. The compound preparation comprises the piracetam pharmaceutical composition and one or more pharmaceutically acceptable auxiliary materials. According to the application, the absorption coefficient of the piracetam medicine can be effectively improved through the combined use of the piracetam medicine and the dextroborneol, so that the bioavailability of the piracetam medicine is improved; when the curative effect is equivalent to that of the piracetam medicine independently used, the combined use of the piracetam medicine and the dextroborneol can reduce the taking dosage of the piracetam medicine, so that the side effects (especially dose-dependent side effects) of the piracetam medicine are reduced.

The application belongs to the technical field of pharmaceutical preparations, and relates to a traditional Chinese medicine self-assembled nanoparticle with enhanced anti-inflammatory activity and a preparation method and application thereof. The traditional Chinese medicine self-assembled nanoparticle is composed of a biphenylcyclooctene type lignan and an oleanane type pentacyclic triterpenoid compound; wherein the mass ratio of the biphenylcyclooctene type lignan and the oleanane type pentacyclic triterpenoid compound is 1:(0.125-8). The application uses a reverse solvent exchange method to prepare a carrier-free nanoparticle based on self-assembly of traditional Chinese medicine active ingredients by using the non-covalent interaction between the biphenylcyclooctene type lignan and the oleanane type pentacyclic triterpenoid compound, significantly reduces cytotoxicity, enhances biocompatibility and reduces toxic side effects, and meanwhile, the traditional Chinese medicine self-assembled nanoparticle has a significant cell uptake effect, improves drug absorption and utilization efficiency, and exhibits higher anti-inflammatory biological activity.

The micro-current phototherapy band-aid comprises a dressing layer, a drug delivery layer and an illumination layer which are sequentially connected from bottom to top, a plurality of drug storage bins are separated in the drug delivery layer, and different drugs are loaded in the drug storage bins; a micro-current power supply, a first conductive strip and a second conductive strip are arranged on the bottom surface of the dressing layer; a plurality of micropores are formed in the dressing layer, and each micropore is communicated with the corresponding medicine storage bin; and a light emitting diode, a driving circuit for enabling the light emitting diode to emit light stably and a driving power supply are arranged in the illumination layer. When the band-aid is used, the micro-current power supply can form dispersed micro-current on a wound surface, blood accumulation and new blood formation are promoted, wound healing and medicine absorption are promoted in combination with an illumination treatment mode brought by the light-emitting diode, meanwhile, the medicine niche on the upper portion enters the skin through the micropores for medicine administration, and comprehensive wound healing treatment is achieved.